Cevec Pharmaceuticals is the leading provider of high performance cell technology for the production of advanced biotherapeutics.
Cevec has now launched the ELEVECTA® platform, a unique technology for the large-scale production of AAV (adeno-associated viral) vectors.
Now Cevec is the first and only supplier on the market offering a technology for the production of AAV gene therapy vectors based on fully stable producer cell lines.
The proprietary technology has been tested in pilot projects with several partners and is now commercially available to pharmaceutical and biotech companies.
NAMBOS developed in an international naming project the new brand name.
The name was derived from the lexical terms element and vector.
This post is also available in: German